GH Research PLC
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorde… Read more
GH Research PLC (GHRS) - Total Liabilities
Latest total liabilities as of December 2025: $8.53 Million USD
Based on the latest financial reports, GH Research PLC (GHRS) has total liabilities worth $8.53 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GH Research PLC - Total Liabilities Trend (2019–2025)
This chart illustrates how GH Research PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GH Research PLC Competitors by Total Liabilities
The table below lists competitors of GH Research PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Yimin Commerce Group Co Ltd
SHG:600824
|
China | CN¥419.03 Million |
|
Shanghai Shenda Co Ltd
SHG:600626
|
China | CN¥6.51 Billion |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
China | CN¥663.71 Million |
|
Guangzhou Anyka Microelectronics Co. Ltd. A
SHG:688620
|
China | CN¥225.54 Million |
|
Pegavision
TW:6491
|
Taiwan | NT$4.44 Billion |
|
WAORF
PINK:WAORF
|
USA | $4.32 Million |
|
Hunan Airbluer Environmental Protection Technology Co. Ltd.
SHE:301259
|
China | CN¥712.45 Million |
|
Tejon Ranch Co
NYSE:TRC
|
USA | $141.00 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down GH Research PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 34.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GH Research PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GH Research PLC (2019–2025)
The table below shows the annual total liabilities of GH Research PLC from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.53 Million | -8.53% |
| 2024-12-31 | $9.32 Million | +27.14% |
| 2023-12-31 | $7.33 Million | +61.28% |
| 2022-12-31 | $4.55 Million | +65.37% |
| 2021-12-31 | $2.75 Million | +1017.48% |
| 2020-12-31 | $246.00K | +136.54% |
| 2019-12-31 | $104.00K | -- |